Kraj: Indonezja
Język: indonezyjski
Źródło: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency
CLONIDINE HYDROCHLORIDE
PYRIDAM FARMA TBK - Indonesia
CLONIDINE HYDROCHLORIDE
0.15 MG
TABLET
DUS, 10 STRIP @ 10 TABLET
DELPHARM REIMS - France
2021-06-23
_1 _ Remarks: BLACK (Current CCDS 0067-03 – Safety Update); BLUE (Latest Approved CCDS 0067-03 for posology update) CATAPRES ® Clonidine hydrochloride COMPOSITION 1 tablet contains 0.075 mg or 0.150 mg 2,6-dichloro-N-2-imidazolidinylidenebenzenamine hydrochloride (= clonidine hydrochloride) Excipients Tablets: Lactose monohydrate, calcium hydrogen phosphate anhydrous, maize starch dried, silica colloidal anhydrous, povidone, starch soluble, stearic acid INDICATIONS CATAPRES is indicated in the treatment of hypertension. CATAPRES may be employed alone or concomitantly with other antihypertensive agents. For the treatment of hypertensive crises, slow parenteral administration is especially suitable due to the rapid onset of action. _RENAL INSUFFICIENCY_ Dosage must be adjusted • according to the individual antihypertensive response which can show high variability in patients with renal insufficiency • according to the degree of renal impairment Careful monitoring is required. Since only a minimal amount of clonidine is removed during routine haemodialysis, there is no need to give supplemental clonidine following dialysis. CONTRAINDICATIONS DOSAGE AND ADMINISTRATION Treatment of hypertension requires regular medical supervision. The dose of CATAPRES must be adjusted according to the patient's individual blood pressure response. TABLETS As an initial daily dose in mild to moderate forms of hypertension, 0.075 mg to 0.150 mg twice daily are sufficient in most cases. After a period of 2 - 4 weeks the dose may be increased if necessary until the desired response is achieved. Usually doses above 0.6 mg per day do not result in a further marked drop in blood pressure. In severe hypertension it might be necessary to increase the single dose further to 0.3 mg; this could be repeated up to three times daily (0.9 mg). DISETUJUI OLEH BPOM: 26/04/2021 EREG100364VR12000487 EREG100364VR12000491 _2 _ Remarks: BLACK (Current CCDS 0067-03 – Safety Update); BLUE (Latest Approved CCDS 0067-03 for posology update) CATAPRES sh Przeczytaj cały dokument